DCM
ANRO icon

Driehaus Capital Management’s Alto Neuroscience ANRO Stock Holding History

Driehaus Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9M Buy
486,726
+149,964
+45% +$2.78M 0.08% 264
2025
Q4 		$5.99M Buy
+336,762
New +$4.24M 0.04% 301

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Driehaus Capital Management's ANRO Position: Q1 2026 in Review

Driehaus Capital Management increased its Alto Neuroscience (ANRO) stake by 45% in Q1 2026, buying an estimated $2.78M and bringing the position to 486,726 shares worth $10.9M. The position accounts for 0.08% of the portfolio, ranked #264.

Driehaus Capital Management first reported a position in ANRO in Q4 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Driehaus Capital Management held 486,726 shares of Alto Neuroscience worth $10.9M as of Q1 2026.
  • Driehaus Capital Management bought 149,964 Alto Neuroscience shares in Q1 2026, an estimated $2.78M.
  • Alto Neuroscience made up 0.08% of Driehaus Capital Management's portfolio in Q1 2026, its #264 holding.
  • Driehaus Capital Management first reported a position in Alto Neuroscience in Q4 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.